GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: MEDI-573
Compound class:
Antibody
Comment: Dusigitumab is an investigational monoclonal antibody which neutralises circulating insulin-like growth factor (IGF)-I and IGF-2. These growth factors regulate cell growth, survival, differentiation, and transformation. Antibody-mediated ligand neutralisation prevents these growth hormones from activating signalling via both IGF1R and IR-A (insulin receptor isoform A, Uniprot identifier P06213-2, RefSeq protein NP_001073285).
Peptide sequence alignment suggests that dusigitumab is antibody 7-159-1 in patent US7939637 [2]. |
Classification ![]() |
|
| Compound class | Antibody |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 9679 | dusigitumab |
Synonyms ![]() |
| MEDI-573 |
Database Links ![]() |
|
| Specialist databases | |
| IMGT/mAb-DB | 451 |
| Other databases | |
| GtoPdb PubChem SID | 223366082 |
| Search PubMed clinical trials | dusigitumab |
| Search PubMed titles | dusigitumab |
| Search PubMed titles/abstracts | dusigitumab |
| Wikipedia | Dusigitumab |